We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01015482
Recruitment Status : Unknown
Verified November 2009 by Medical University of Vienna.
Recruitment status was:  Recruiting
First Posted : November 18, 2009
Last Update Posted : November 18, 2009
Information provided by:

November 17, 2009
November 18, 2009
November 18, 2009
November 2009
March 2010   (Final data collection date for primary outcome measure)
Measure: Area of pin prick hyperalgesia [ Time Frame: 0-6h ]
Same as current
No Changes Posted
  • Stimulus-response (SR) function to a set of modified rigid von Frey filaments (8-512 mN) [ Time Frame: 0-6h ]
  • Heat pain threshold within the area of mechanical hyperalgesia [ Time Frame: 0-6h ]
  • Mechanical pain threshold within the area of pin prick hyperalgesia, area of dynamic allodynia to brush [ Time Frame: 0-6h ]
  • Adverse effects [ Time Frame: 30 and 59 min after start of treatment ]
Same as current
Not Provided
Not Provided
The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)
The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)

Treatment of chronic pain is a major clinical challenge since chronic pain is frequent and leads to deterioration of quality of life. An injury or wound can lead to long term changes in the nervous system that make the skin more sensitive at and near the injury; this is termed hyperalgesia and occurs through long term depotentiation (LTP), i.e., a change in the synaptic interaction between neurons.

Opioids are the gold standard for the symptomatic therapy of moderate to severe pain. Now, in animal studies the investigators have discovered previously unrecognized effects of opioids.

UV-B irradaition of the skin of the thigh is an established model of priamary and secondary hyperalgeisa in humans. The investigators want to test the influence of remifentanil, an ultra-short acting opioid, on hyperalgesia observed after UV-B irradiation in human volunteers in a double blind cross-over prospective active placebo controlled clinical trial, at a dose corresponding to 0.7 µg kg-1 min-1.

Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
  • Drug: Remifentanil
    Remifentanil Infusion
    Other Name: Ultiva
  • Drug: Midazolam
    Midazolam Infusion
    Other Name: Dormicum
  • Experimental: Remifentanil
    Remifentanil Infusion
    Intervention: Drug: Remifentanil
  • Active Comparator: Midazolam
    Active Placebo
    Intervention: Drug: Midazolam
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
April 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Body mass index between 15th and 85th percentile
  • Normal findings in the medical history and physical examination
  • Drug free for 1 week prior to the study day

Exclusion Criteria:

  • Regular use of medication especially analgesics
  • Abuse of alcoholic beverages, drug abuse
  • History of asthma
  • Participation in a clinical trial in the 2 weeks preceding the study
  • Symptoms of a clinically relevant illness in the 2 weeks before the first study day
  • Resting systolic blood pressure > 135 mmHg or diastolic blood pressure > 85 mmHg
  • Acute skin diseases like sunburn on the relevant areas or skin lesions
  • Pregnancy or breast feeding
  • UV sensitive skin conditions, like Xeroderma pigmentosa
Sexes Eligible for Study: All
19 Years to 40 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
HighDose RemiSun
Not Provided
Not Provided
Professor Burkhard Gustorff, Medical University of Vienna, Dept. Anaesthesia
Medical University of Vienna
Not Provided
Principal Investigator: Astrid Chiari, MD Medical University of Vienna
Medical University of Vienna
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP